1.
Clin Lymphoma Myeloma Leuk
; 13(6): e18-21, 2013 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24060286
Assuntos
Linfoma Difuso de Grandes Células B/diagnóstico , Neoplasias Vasculares/diagnóstico , Anticorpos Monoclonais Murinos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Medula Óssea/patologia , Aberrações Cromossômicas , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Humanos , Imunofenotipagem , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/patologia , Masculino , Pessoa de Meia-Idade , Prednisona/uso terapêutico , Rituximab , Resultado do Tratamento , Neoplasias Vasculares/tratamento farmacológico , Neoplasias Vasculares/patologia , Vincristina/uso terapêutico
2.
Cancer Genet Cytogenet
; 182(2): 126-9, 2008 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18406875
RESUMO
Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS. Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.